Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Will the recent positive trend continue leading up to its next earnings release, or is Kymera Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Kymera Q2 Loss Narrower Than Expected, Pipeline in Focus Kymera Therapeutics reported a loss of 58 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, Kymera reported a loss of 67 cents per share. Loss narrowed in the quarter due to higher revenues. Collaboration revenues totaled $25.6 million, which beat the Zacks Consensus Estimate of $12 million. The reported figure increased 55.3% from the year-ago quarter's level. Collaboration revenues in the second quarter were mostly earned due to the company's association with bigwig Sanofi. Quarter in Detail Research and development
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Participate in Upcoming February Investor ConferencesGlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $60.00 price target on the stock.MarketBeat
- Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewswire
- Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 10/31/24 - Beat
KYMR
Sec Filings
- 2/10/25 - Form SCHEDULE
- 1/14/25 - Form 8-K
- 1/13/25 - Form 4
- KYMR's page on the SEC website